Oncology

Latest News

AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com
Ensuring Coverage of Faster Biomarker Testing in Lung Cancer: Robert Kratzke, MD

July 15th 2025

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com
Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Insurance gaps | Image Credit: iQoncept-stock.adobe.com
Insurance Gaps Threaten Cancer Treatment Success

July 7th 2025

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski
Decline in SCLC Incidence Expected to Accelerate Through 2050

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

June 27th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
July 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Chelsee Jensen, PharmD, BCPS | Image credit: LinkedIn
February 24th 2025

Price Caps During Accelerated Approval Would Help Address Financial Toxicity for Patients, Jensen Says

Chelsee J. Jensen, PharmD, BCPS Interview by Mary Caffrey
Health care institutions with large numbers of Medicare and Medicaid patients may be constrained from offering cancer therapies made available under the accelerated approval pathway.
Cervical cancer awareness | Image Credit: © WhalewithMoon-stock.adobe.com
February 24th 2025

Health System Policy Failures Drive Cervical Cancer Disparities in Rural South

Maggie L. Shaw
The Southern Rural Black Women’s Initiative for Economic and Social Justice works to overcome race, class, cultural, religious, and gender barriers that Black women and young women face in the rural South, specifically the Mississippi Delta and the Black Belt regions of Alabama and Georgia.
Screenshot of an interview with Shaun McKenzie, MD
February 23rd 2025

Histotripsy May Expand Beyond Liver Tumors, but Long-Term Data Are Still Needed

Laura Joszt, MA Shaun P. McKenzie, MD, FACS
Although histotripsy can successfully destroy tumors in the liver, longer-term data are still needed to see recurrence rates and overall survival, said Shaun P. McKenzie, MD, FACS, a surgical oncologist with Texas Oncology.
Screenshot of an interview with Rohan Garje, MD
February 21st 2025

Barriers That Prevent Access to Optimal Treatment in Primary Urethral Cancer

Laura Joszt, MA Rohan Garje, MD
Eligibility issues, a need for better multidisciplinary collaboration, and a lack of incorporation in community practices are all barriers to the use of neoadjuvant chemotherapy followed by surgery for patients with primary urethral cancer, said Rohan Garje, MD.
Susan Escudier, MD, FACP
February 21st 2025

The Need for Payer Support in Overcoming Cancer Care Disparities

Hayden E. Klein Susan Escudier, MD, FACP
Susan Escudier, MD, FACP, discusses the impact of insurance coverage gaps, transportation barriers, and financial hardships on cancer care access and emphasizes the need for payers to better support patients at high risk.
Alicia Morgans MD, MPH | Image credit: Dana-Farber
February 20th 2025

Getting More Doctors to Record a Life-Saving Prostate Cancer Calculation

Mary Caffrey
Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is often missed by doctors, impacting patient care.
Sabarish Ayyappan, MD
February 20th 2025

Geographic Barriers Impede Access to Novel Cancer Treatments

Kyle Munz Sabarish Ayyappan, MD
In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.
Fueling Cancer Research Breakthroughs With Patient Contributions
February 20th 2025

Fueling Cancer Research Breakthroughs With Patient Contributions

Maggie L. Shaw Karen Winkfield, MD, PhD
In part 3 of this conversation, Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance, discusses why basic scientific research remains essential and how patient experiences contribute.
Patient talking with doctor | Image credit: Monkey Business - stock.adobe.com
February 20th 2025

Cancer Mortality Rates Still High Among Black Patients, Despite Overall Decline

Julia Bonavitacola
Black individuals had a 2-fold risk of cancer death related to prostate, myeloma, and stomach cancers compared with White individuals.
Vivek Murthy, MD | Image credit: NBC News
February 19th 2025

Alcohol and Cancer Risk: Murthy’s Parting Call for Warning Labels

Maggie L. Shaw
radiology x-ray lung cancer | Image credit: utah51 – stock.adobe.com
February 17th 2025

2 Immunotherapies Show Comparable Benefits in Extensive-Stage Small Cell Lung Cancer

Hayden E. Klein
When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 and PD-L1 inhibitors.
Susan Escudier, MD, FACP
February 17th 2025

Addressing Financial Toxicity and Clinical Trial Disparities in Community Oncology

Hayden E. Klein Susan Escudier, MD, FACP
Susan Escudier, MD, FACP, explains some of the ways Texas Oncology mitigates financial toxicity and improve clinical trial access for underserved patients.
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025

Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302

Mary Caffrey
The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025

Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer

Mary Caffrey
City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Screenshot of an interview with Evangelia Vlachou, MD
February 14th 2025

Enfortumab Vedotin With or Without Pembrolizumab Delivers Promising Responses for Upper Tract Urothelial Cancer

Laura Joszt, MA Evangelia Vlachou, MD
Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.
Screenshot of an interview with Barry Goy, MD
Published: February 14th 2025 | Updated: February 14th 2025

Receiving NADT for 6 Months Doesn’t Impact Outcomes in Intermediate-Risk Prostate Cancer After EBRT

Laura Joszt, MA Barry Goy, MD
Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), according to 15-year outcomes presented by Barry Goy, MD, of Kaiser Permanente.
Metastatic urothelial carcinoma. | Image Credit: MdBabul - stock.adobe.com
February 13th 2025

ASCO GU Posters Address Cost-Effectiveness, Implementation Barriers for New mUC Treatments

Cameron Santoro
Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into practice due to high costs and a lack of targeted initiatives to aid health care providers with integration.
Positive OS for Bladder Cancer Combo, Biomarkers on Tap at ASCO GU 2025
February 11th 2025

Positive OS for Bladder Cancer Combo, Biomarkers on Tap at ASCO GU 2025

Mary Caffrey
Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
Debra Patt, MD, PhD, MBA, MPH
February 10th 2025

The “Secret Sauce” in Oncology: The Partnership Between Clinicians and AI

Mary Caffrey Debra Patt, MD, PhD, MBA, MPH
“To error is human, and also to error is in machine learning,” said Debra Patt, MD, PhD, MBA, MPH.
Burning cigarette | Image Credit: nikkytok - stock.adobe.com
February 10th 2025

Pain Linked to Greater Cigarette, E-Cigarette, Cannabis Use Among Cancer Survivors

Brooke McCormick
These new data highlight the need for improved pain management among patients with cancer and survivors.
Terra Wonsettler, PharmD, MBA | Image credit: Evolent
February 7th 2025

Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”

Terra Wonsettler, PharmD, MBA Interview by Mary Caffrey
Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Doctor showing patient lung x-ray. | Image credit: Dragana Gordic – stock.adobe.com
February 7th 2025

Study Finds Declining SCLC Incidence, but Stagnant Survival Rates

Hayden E. Klein
SEER data show that small cell lung cancer (SCLS) incidence has steadily declined due to reduced smoking rates, but survival outcomes have seen only minimal improvement, underscoring the need for more effective treatments.
AJMC
February 7th 2025

Hospitalization Patterns Among Older Patients With Cancer With and Without Dementia

Zhigang Xie, PhD, MPA Hanadi Y. Hamadi, PhD Elissa Barr, PhD Beomyoung Cho, PhD, MPH Shraddha Patel, MPH Young-Rock Hong, PhD, MPH
Dementia was more prevalent in older patients with some cancer types, and comorbid dementia in this population was associated with unplanned or unnecessary hospitalization.
Older man after skin cancer surgery with bandage on face | Image credit: steheap – stock.adobe.com
February 7th 2025

Keratinocyte Skin Cancer Surgery Considered Safe, Effective in Older Patients

Hayden E. Klein
A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.
Flatiron Health, Exact Sciences Announce Deal to Speed Evidence Generation With MRD Test
February 6th 2025

Flatiron Health, Exact Sciences Announce Deal to Speed Evidence Generation With MRD Test

AJMC Staff
The companies announced the deal in a statement February 5, 2025, noting that the first patient had enrolled in a prospective clinical study using the test to monitor cancer recurrence across multiple solid tumor types.
Clayton Irvine, PharmD, MBA, MS.
February 6th 2025

Addressing Cancer Treatment Costs With Patient-Provider Communication

Cameron Santoro Clayton Irvine, PharmD, MBA, MS
Clayton Irvine, PharmD, MBA, MS, senior manager of oncology care at Mayo Clinic, emphasizes the need for health care providers to balance quality patient care with rising costs by openly discussing financial implications with patients and educating themselves on cost-effective treatments.
Debra Patt, MD, PhD, MBA, MPH
February 6th 2025

Dr Debra Patt on Prior Authorization: Something Has to Give

Mary Caffrey Debra Patt, MD, PhD, MBA, MPH
Debra Patt, MD, PhD, MBA, MPH, warns that prior authorization barriers are delaying critical cancer treatments and urges a regulatory fix for Stark Law restrictions on mailing oral oncolytics.
AI concept of cancer vaccine | Image credit: radekcho - stock.adobe.com
February 5th 2025

Promising Cancer Vaccine Boosts Hope for Stage III and IV Kidney Cancer

Pearl Steinzor
All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.
COA Offers “Prescription” for Tackling Rising Costs, Loss of Patient Access in Cancer Care and Beyond
February 5th 2025

COA Offers “Prescription” for Tackling Rising Costs, Loss of Patient Access in Cancer Care and Beyond

Mary Caffrey
The 5-part plan focuses on issues that have been calling cards for the Community Oncology Alliance (COA) in recent years, which gained traction in the last Congress and show up regularly on lists of the most pressing problems in health care.
Debra Patt, MD, PhD, MBA, MPH
February 4th 2025

Dr Debra Patt Pushes for PBM Reform and Physician Reimbursement Fixes

Mary Caffrey Debra Patt, MD, PhD, MBA, MPH
Debra Patt, MD, PhD, MBA, MPH, emphasizes advocacy for pharmacy benefit manager (PBM) reform, physician reimbursement, and sustainable policy solutions to improve access to community cancer care.
<12345678
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo